First, keep one caregiver account in its proper place
A July 28 post in r/dementia described a family member trying to understand new behavior, a low-dose antipsychotic, and a referral whose purpose was unclear. The writer first understood it as psychotherapy, then said later paperwork suggested medication management. Commenters offered opinions, but none could inspect the resident's record.
The account does not verify the diagnosis, target symptoms, order, administration history, interventions, response, adverse effects, referral instructions, or clinician reasoning. Its useful signal is narrower: when class, role, and response labels blur, can the next authorized reviewer reconstruct the open question? The post describes memory care, not a verified Medicare- or Medicaid-certified nursing facility, so Appendix PP cannot be presumed to govern that account or referral.
1. Write the FDA boundary before discussing a class
On April 30, 2026, FDA approved an expanded use for Auvelity, a combination of dextromethorphan and bupropion, for agitation associated with dementia due to Alzheimer's disease in adults. FDA called it the first approved treatment for that condition that is not an antipsychotic. The prescribing information says it is not indicated as an as-needed, or PRN, treatment for that use.
That language sets a boundary; it does not select treatment for a resident. The approval does not cover every form of dementia, every difficult behavior, or every use of either ingredient. Name the diagnosed condition and intended indication exactly, leave clinical decisions to the responsible clinicians, and preserve the resident's or representative's role in informed participation.
2. Replace ‘agitation’ with an observable baseline
A broad word such as agitation, aggression, or distress cannot show whether anything changed. Preserve the specific behavior or symptom, when and where it occurred, its frequency or severity, who observed it, and the effect on the resident or others. Keep sudden change and possible contributing conditions visible rather than assuming one cause.
This is not a homemade diagnostic scale. It is a dated description that lets an authorized clinician compare like with like. When staff use different terms, retain their source and wording instead of inventing a consensus.
3. Name the product, ingredients, and order state
Record the generic and brand names, both ingredients in a combination product, strength, form, schedule, change date, prescriber, and current order state. The Auvelity label tells health professionals to determine whether a patient receives other medicines containing bupropion or dextromethorphan; a brand-only list can conceal that question.
Do not turn reconciliation into an automatic stop, substitution, or diagnosis. Surface an ingredient or order question to the responsible clinician and preserve the resulting decision.
4. Keep ‘not an antipsychotic’ separate from CMS psychotropic scope
CMS Appendix PP defines psychotropic drugs broadly and lists antipsychotic, antidepressant, antianxiety, and hypnotic categories. Being outside the antipsychotic class does not by itself answer whether wider psychotropic requirements apply.
For a Medicare- or Medicaid-certified nursing facility, use current regulation, survey guidance, product information, facility policy, and professional judgment to review the actual regimen. Do not carry an antipsychotic measure label into another class—or use its absence as a shortcut around the resident record.
5. Make the referral say what work is being requested
Psychotherapy, psychiatry, behavioral assessment, medication management, and care coordination are not interchangeable instructions. A referral should answer three practical questions: which service is requested, what question should it answer, and who will act on the result. Then note what was sent and when the next update is due.
The discussion shows how quickly a vague title can become an assumed treatment plan. A referral received is not an evaluation completed, and an evaluation is not a medication decision. Keep those states separate so the family, facility, prescriber, and consultant pharmacist are not waiting for different events behind one status.
6. Connect interventions, response, and uncertainty
CMS guidance addresses diagnosed and documented conditions, behavioral interventions, monitoring, resident response, and gradual dose reduction unless clinically contraindicated. It also calls for rationale when an antipsychotic is switched to another psychotropic category. Those requirements do not dictate the answer for a resident; they make the basis for a decision inspectable.
Place medication and nonpharmacological approaches on one timeline without treating them as equivalent. Record what was tried, when, the observation source, the documented response or adverse effect, and what remains unknown. ‘Not working’ calls for a baseline and observation window, not an automatic increase or switch.
7. End with the next decision, owner, and evidence
The handoff needs one plain sentence: what decision is pending, who will make it, what information is missing, and when the team will look again. Before a psychotropic medication is initiated or increased in a covered nursing-facility setting, CMS guidance calls for documenting that the resident or representative was informed in advance about benefits, risks, and alternatives and could choose the preferred option.
Test one appropriately authorized record or a synthetic case. A covering pharmacist should be able to distinguish FDA indication, medication class, CMS scope, referral purpose, observations, rationale, and unfinished work. If the record shows only ‘antipsychotic,’ ‘non-antipsychotic,’ or ‘referred,’ the important part of the story is missing.